S0820, Adenoma and Second Primary Prevention Trial

The investigators hypothesize that the combination of eflornithine and sulindac will be
effective in reducing a three-year event rate of adenomas and second primary colorectal
cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

Intervention

Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac

Condition

Colorectal Neoplasms

Investigators

Jason A. Zell, D.O., MPH, Kathleen J. Yost, Philip J. Stella, David M. King, Carroll D. Scroggin, Shaker R. Dakhil, Samantha A. Seaward, John A. Ellerton, Deborah W. Wilbur, Amitpal S. Johal, Carl J. Minniti, Michal G. Rose, Matthew L. Ryan, James H. Feusner, Jay W. Carlson, Chung-Tsen Hsueh, Bret E. Friday, James E. Radford, William P. Fusselman, Sukeshi P. Arora, Shailja Roy, Howard A. Zaren, Donald J. Jurgens, January Fields-Meehan, Salvatore A. Del Prete, David A. Mullins, James E. Clarkson, Burke J. Brooks, Donald B. Wender, Sagila George, Robert J. Behrens, Tomislav Dragovich, Arvinder S. Bir, Thomas J. Reid, Gamini S. Soori, Bryan A. Faller, Mark F. Kozloff, Mitchell Haut, Richard L. Deming, Uzair B. Chaudhary, Ari D. Baron, Mehmet Akce, Chady A. Leon, Anthony F. Shields, Akm Mosharraf Hossain, Harish G. Ahuja, Sajid A. Khan, Kendrith M. Rowland, Stuart A. Krauss, Shylendra B. Sreenivasappa, Isoken Koko, Pashtoon M. Kasi, Gina G. Chung, Sunitha Vemulapalli, Jason A. Zell, Joshua E. Melson, Bernard M. Evers, Sarah M. Popek, Nina Beri, Howard M. Gross, Gene B. Saylors, Britt H. Olmsted, Mohammed Saad, Gary L. Buchschacher, Leon C. Hwang, Stephen K. Williamson, Nagesh H. Jayaram, Mustapha A. Khalife, Martin D. McCarter, Ahmad Shaker, Ryan T. Oleszewski, Susan E. Lyons, Vincent P. Vinciguerra

See list of participating sites